Alder Gets $38M Series D for Pipeline as BMS Carries Lead
By Trista Morrison
Friday, April 20, 2012
With partner Bristol-Myers Squibb Co. handling all costs for lead antibody ALD518 in autoimmune disease, Alder BioPharmaceuticals Inc. can apply the $38 million it just raised in Series D financing to its internal pipeline.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.